Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Trial ID or NCT#
NCT01254045
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate behaviors and reducing social anxiety.
Official Title
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Eligibility Criteria
Ages Eligible for Study: 13 Years to 29 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Inclusion Criteria:
- 1. Confirmed genetic diagnosis of Fragile X (FraX) (full mutation). 2. Male (who have more serious effects due to the X chromosome nature of the disorder) 3. Age 13-29 years. 4. Parent of adolescent must be willing to sign informed consent. 5. Intelligence Quotient (IQ) > 42.
Exclusion Criteria:
- 1. Cardiac risk factors. 2. Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or atypical antipsychotics.
Investigator(s)
Allan L. Reiss
Contact us to find out if this trial is right for you.
Contact
Scott Hall
6504984799
View on ClinicalTrials.gov
